Cyclosporine A loaded brain targeting nanoparticle to treat cerebral ischemia/reperfusion injury in mice

Liu, Daozhou; Q, Ji; Cheng, Ying; Liu, Miao; Zhang, Bang-Le; Mei, Qibing; Huan, Meng‐Lei; Zhou, Siyuan

doi:10.1186/s12951-022-01474-x

Cited by 20 publications

(14 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Previous findings have shown that CsA is capable of preventing ischemic brain injury by inhibiting the massive activation of microglia and the production of cytokines in rats with chronic cerebral hypoperfusion. 33 Microglia are of great significance in central sensitization and the development of NP. Abnormally activated microglia following peripheral nerve injury causes abnormal excitation of spinal dorsal horn neurons by releasing neuromodulators.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Cyclophilin A-Metalloproteinase-9 Pathway Alleviates the Development of Neuropathic Pain by Promoting Repair of the Blood-Spinal Cord Barrier

Wang,

Yang

et al. 2023

Anesthesia &Amp; Analgesia

View full text Add to dashboard Cite

BACKGROUND: Dysfunction of the blood-spinal cord barrier (BSCB) contributes to the occurrence and development of neuropathic pain (NP). Previous studies revealed that the activation of cyclophilin A (CypA)-metalloproteinase-9 (MMP9) signaling pathway can disrupt the integrity of the blood-brain barrier (BBB) and aggravate neuroinflammatory responses. However, the roles of CypA-MMP9 signaling pathway on BSCB in NP have not been studied. This study aimed to investigate the effect of CypA on the structure and function of the BSCB and pain behaviors in mice with NP. METHODS: We first created the mouse chronic constriction injury (CCI) model, and they were then intraperitoneally injected with the CypA inhibitor cyclosporine A (CsA) or vehicle. Pain behaviors, the structure and function of the BSCB, the involvement of the CypA-MMP9 signaling pathway, microglia activation, and expression levels of proinflammatory factors in mice were examined. RESULTS: CCI mice presented mechanical allodynia and thermal hyperalgesia, impaired permeability of the BSCB, downregulated tight junction proteins, activated CypA-MMP9 signaling pathway, microglia activation, and upregulated proinflammatory factors, which were significantly alleviated by inhibition of CypA. CONCLUSIONS: Collectively, the CypA-MMP9 signaling pathway is responsible for CCI-induced NP in mice by impairing the structure and function of the BSCB, and activating microglia and inflammatory responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of Cyclophilin A-Metalloproteinase-9 Pathway Alleviates the Development of Neuropathic Pain by Promoting Repair of the Blood-Spinal Cord Barrier

Wang,

Yang

et al. 2023

Anesthesia &Amp; Analgesia

View full text Add to dashboard Cite

show abstract

“…Cerebral I/R C-Rp-NPs [262] 𝛾-L-Glu-L-Cys -73.37 ± 1.43 -25.7 ± 0.57 Rp Cerebral I/R CsA@HFn [ 273] Ferritin (Fn) -26 -CsA…”

Section: Cardiac Arrest/cardiopulmonary Resuscitation-induced Brain I...mentioning

confidence: 99%

Revitalizing Ancient Mitochondria with Nano‐Strategies: Mitochondria‐Remedying Nanodrugs Concentrate on Disease Control

Long,

Liu,

Nan

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Mitochondria, widely known as the energy factories of eukaryotic cells, have a myriad of vital functions across diverse cellular processes. Dysfunctions within mitochondria serve as catalysts for various diseases, prompting widespread cellular demise. Mounting research on remedying damaged mitochondria indicates that mitochondria constitute a valuable target for therapeutic intervention against diseases. But the less clinical practice and lower recovery rate imply the limitation of traditional drugs, which need a further breakthrough. Nanotechnology has approached favorable regiospecific biodistribution and high efficacy by capitalizing on excellent nanomaterials and targeting drug delivery. Mitochondria‐remedying nanodrugs have achieved ideal therapeutic effects. In this review, we have elucidated the significance of mitochondria in various cells and organs, while also compiling mortality data for related diseases. Correspondingly, nanodrug‐mediate therapeutic strategies and applicable mitochondria‐remedying nanodrugs in disease were detailed, with a full understanding of the roles of mitochondria dysfunction and the advantages of nanodrugs. In addition, the future challenges and directions have been widely discussed. In conclusion, this review provides comprehensive insights into the design and development of mitochondria‐remedying nanodrugs, aiming to help scientists who desire to extend their research fields and engage in this interdisciplinary subject.This article is protected by copyright. All rights reserved

show abstract

“…In contrast, the neuroprotective cytokine IL-10 was significantly increased. [259] Poly(dopamine) NPs (PDA NPs), as the name implies, are nanostructures obtained from the polymerization of dopamine into poly(dopamine), an artificial melanin-like material. [260] PDA NPs are a promising polymeric-like candidate for treating CNS diseases, as they possess antioxidant properties attributed to their abundant phenolic hydroxyl groups.…”

Section: Organic Nanostructuresmentioning

confidence: 99%

Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders

Battaglini,

Marino,

Montorsi

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Microglia play a pivotal role in the central nervous system (CNS) homeostasis, acting as housekeepers and defenders of the surrounding environment. These cells can elicit their functions by shifting into two main phenotypes: pro‐inflammatory classical phenotype, M1, and anti‐inflammatory alternative phenotype, M2. Despite their pivotal role in CNS homeostasis, microglia phenotypes can influence the development and progression of several CNS disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, ischemic stroke, traumatic brain injuries, and even brain cancer. It is thus clear as the possibility of modulating microglia activation has gained attention as a therapeutic tool against many CNS pathologies. Nanomaterials are an unprecedented tool for manipulating microglia responses, in particular to specifically target microglia and elicit an in situ immunomodulation activity. In this review we will focus our discussion on two main aspects: we will analyze the possibility of using nanomaterials to stimulate a pro‐inflammatory response of microglia against brain cancer and we will introduce nanostructures able to foster an anti‐inflammatory response for treating neurodegenerative disorders. The final aim is to stimulate the analysis of the development of new microglia nano‐immunomodulators, paving the way for innovative and effective therapeutic approaches for the treatment of CNS disorders.This article is protected by copyright. All rights reserved

show abstract

Cyclosporine A loaded brain targeting nanoparticle to treat cerebral ischemia/reperfusion injury in mice

Cited by 20 publications

References 55 publications

Inhibition of Cyclophilin A-Metalloproteinase-9 Pathway Alleviates the Development of Neuropathic Pain by Promoting Repair of the Blood-Spinal Cord Barrier

Inhibition of Cyclophilin A-Metalloproteinase-9 Pathway Alleviates the Development of Neuropathic Pain by Promoting Repair of the Blood-Spinal Cord Barrier

Revitalizing Ancient Mitochondria with Nano‐Strategies: Mitochondria‐Remedying Nanodrugs Concentrate on Disease Control

Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders

Contact Info

Product

Resources

About